Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

113 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues in deep venous thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) is associated with an improvement of the treatment satisfaction after 3 months. The treatment satisfaction will be measured by the Anti Clot Treatment Scale (ACTS) score.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

NCT02111564

Heart Failure Respiratory Insufficiency Stroke Acute +2 more

COMPLETED PHASE3

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

NCT01619007

Deep Vein Thrombosis Venous Thrombosis

COMPLETED

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

NCT02064439

Pulmonary Embolism Thromboembolism Thrombosis +2 more

COMPLETED PHASE3

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216

Peripheral Artery Disease

COMPLETED PHASE3

Switching Study From Warfarin to Rivaroxaban

NCT01507051

Venous Thrombosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rivaroxaban

20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment

Rivaroxaban (Xarelto, BAY59-7939)

Intervention Type DRUG

20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban (Xarelto, BAY59-7939)

20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female or male subject ≥ 18 years of age,
* With a diagnosis of acute DVT treated with VKA with issues for at least the 4 previous weeks (issues are assessed on medical judgment)
* Who intends to start rivaroxaban for treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT
* With anticoagulation therapy planned for at least 3 months

Exclusion Criteria

* Contra indication to the use of Xarelto as described in the Summary of Product Characteristics (SmPC); key contra indications are:

* Hypersensitivity to the active substance or to any of the excipients listed in SmPC section 6.1.
* Lesion or condition at significant risk of major bleeding
* Concomitant treatment with any other anticoagulant agent
* Clinically significant active bleeding
* Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C
* Pregnancy and breast feeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No